RCMI Coordinating Center (RCMI CC) Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Lopez-Ribot, Jose L.
One or more keywords matched the following properties of Lopez-Ribot, Jose L.
PropertyValue
overview Dr. Lopez-Ribot’s lab studies fungal infections, with an emphasis on the opportunistic pathogenic fungus Candida albicans. The pathogen is capable of causing overt disease (candidiasis), but usually only in hosts with defective immunity. Candidiasis is now the third to fourth most common nosocomial, hospital-acquired, infection. Studies in the lab work to integrate "microorganism-centered" and "host-centered" facets to better understand C. albicans pathogenesis. Some of the highlights of this research program include: a) development of novel immune-based therapies to combat candidiasis, b) the role of morphogenetic conversions in the pathogenesis of candidiasis, and c) the study of C. albicans biofilms. Other areas of interest in Dr. Lopez-Ribot’s lab include genomics and proteomics, cell wall and adhesion, antifungal drug resistance, development of diagnostic techniques for candidiasis, and high throughput screening for antifungal drug discovery. Main projects in the lab deal with targeting virulence factors, more specifically filamentation and biofilm formation, for the development of novel antifungal agents, and with developing microbial chips as a new universal technology platform for microbial culture at the nanoscale level.
One or more keywords matched the following items that are connected to Lopez-Ribot, Jose L.
Item TypeName
Academic Article High-throughput nano-biofilm microarray for antifungal drug discovery.
Academic Article Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening.
Academic Article High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation.
Academic Article Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors.
Academic Article Screening a Commercial Library of Pharmacologically Active Small Molecules against Staphylococcus aureus Biofilms.
Academic Article Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.
Academic Article FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal.
Academic Article Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
Concept High-Throughput Screening Assays
Academic Article High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors.
Academic Article Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation.
Academic Article A Facile High-Throughput Model of Surface-Independent Staphylococcus aureus Biofilms by Spontaneous Aggregation.
Academic Article Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation.
Academic Article A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening.
Academic Article High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms.
Search Criteria
  • Mass Screening
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support